$1.34
Price
$155M
Market Cap
—
P/E Ratio
-1.2
Forward P/E
$-1.33
EPS (TTM)
—
Dividend Yield
$215M
Cash
$85M
Total Debt
115M
Shares Out
$0.66
$1.94
52-Week Range
Institutional Ownership of FATE THERAPEUTICS INC
|
Fund / Manager
Click to search
|
Shares | Value | % of Portfolio | Cost Basis | Est. Return |
|---|---|---|---|---|---|
| No funds currently hold this stock. | |||||
Trading Activity for FATE THERAPEUTICS INC
|
Fund / Manager
Click to search
|
Action | Change | Shares After | Value | Price |
|---|---|---|---|---|---|
| 2021-Q4 | |||||
| SELL | EXIT | — | — | $56.51 | |
| 2021-Q1 | |||||
| BUY | +98.0% | 1.7M | $144M | $95.69 | |
| 2020-Q4 | |||||
| BUY | NEW | 883.7K | $80M | $51.98 | |
Insider Trading for FATE THERAPEUTICS INC
6 Months Insider Sentiment
Buy $0
Sell $17K
0
Buys
2
Sells
-17K
Net
1
Grants
Largest
$11K
Tahl
$6K
Valamehr
| Date |
Insider
Click to search
|
Role
Click to search
|
Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jan 09, 2026 | Bahram Valamehr | President and CEO | SELL | 5.2K | $1.07 | $6K |
| Jan 09, 2026 | Cindy Tahl | Chief Legal and Compliance Officer | SELL | 10.6K | $1.06 | $11K |
| Oct 20, 2025 | Kamal Adawi | Chief Financial Officer | GRANT | 75.0K | — | — |